A Pilot, Open-Label, Non-Randomized, Single Ascending Dose, Safety and Pharmacokinetic Trial With Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder

Trial Profile

A Pilot, Open-Label, Non-Randomized, Single Ascending Dose, Safety and Pharmacokinetic Trial With Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2013

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 02 May 2013 Positive top-line results from 100mg dose extension reported in a Zogenix media release.
    • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jan 2013 Positive pharmacokinetic and safety results were announced in a Zogenix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top